Diabetic & Hypertensive Retinopathy
A board-focused ophthalmology lesson contrasting diabetic and hypertensive retinopathy by findings, stage, and next-best-step management, anchored on classic vignette buzzwords. Covers NPDR/PDR, DME, VEGF-driven neovascularization, the Keith-Wagener-Barker grades, malignant hypertension with correct graded BP-lowering targets, and the ETDRS 4-2-1 rule.
Two microvascular retinopathies, side by side
Diabetic and hypertensive retinopathy are the two retinal vascular diseases the boards love to contrast. Both damage retinal arterioles and capillaries, and both can show cotton wool spots (nerve-fiber-layer microinfarcts) and hard exudates — so the exam distinguishes them by the company those findings keep.
Diabetic retinopathy stems from chronic hyperglycemia causing pericyte loss, capillary leakage, and ischemia; it is the leading cause of blindness in working-age adults. Retinal ischemia drives VEGF release — the switch that turns non-proliferative disease into sight-threatening neovascularization.
Hypertensive retinopathy reflects the arteriolar response to elevated blood pressure. Chronic changes (AV nicking, copper/silver wiring) signal duration; acute changes (flame hemorrhages, exudates, disc edema) signal severity and, at the extreme, malignant hypertension.
Approach every vignette the same way: key findings → stage → next best step.
- Earliest sign: microaneurysms (outpouchings of weakened capillaries)
- NPDR (non-proliferative): dot-blot hemorrhages, hard exudates (lipid), cotton wool spots, venous beading, IRMA — but no neovascularization
- PDR (proliferative): neovascularization of disc/retina driven by VEGF from ischemia → vitreous hemorrhage, tractional retinal detachment, neovascular glaucoma (rubeosis iridis)
- #1 cause of vision loss in diabetics = diabetic macular edema (DME) — can occur at any stage
- Screening (dilated exam): Type 1 DM → 5 years after diagnosis; Type 2 DM → at diagnosis; then annually; pre-existing DM in pregnancy → first trimester, then each trimester
- Tight glycemic, BP, and lipid control slows progression
Vignette: A 58-year-old man with a 15-year history of poorly controlled type 2 diabetes reports sudden, painless loss of vision in the right eye with new floaters and a reddish haze. No pain or redness. The fundus view is obscured by blood.
Diagnosis: Vitreous hemorrhage from proliferative diabetic retinopathy — fragile neovessels bled.
Next best step: Ocular B-scan ultrasound to see the retina behind the blood and rule out tractional retinal detachment. Treat the underlying PDR with panretinal photocoagulation (PRP) and/or anti-VEGF; vitrectomy if the hemorrhage fails to clear or a tractional detachment threatens the macula.
Contrast: central retinal artery occlusion (painless loss but pale retina + cherry-red spot) and retinal detachment (a curtain/shade with flashes).
- Chronic (duration) changes: generalized/focal arteriolar narrowing, AV nicking, copper → silver wiring
- Acute (severity) changes: flame hemorrhages (superficial nerve-fiber layer), cotton wool spots, hard exudates radiating as a macular star, optic-disc edema
- Keith-Wagener-Barker grades: I = mild arteriolar narrowing; II = AV nicking + focal narrowing; III = grade II + hemorrhages, cotton wool spots, exudates; IV = grade III + papilledema
- Grade IV (papilledema) = malignant hypertension — a hypertensive emergency with end-organ damage
- Flame hemorrhages are superficial; diabetic dot-blot hemorrhages are deep — the layer names the disease
Vignette: A 47-year-old man presents with headache and blurred vision. BP is 215/135 mmHg. Fundoscopy shows flame hemorrhages, cotton wool spots, a macular star, and bilateral optic disc swelling (papilledema).
Diagnosis: Malignant hypertension with grade IV hypertensive retinopathy — a hypertensive emergency (acute end-organ damage).
Next best step: Admit and lower BP with a titratable IV antihypertensive (e.g., labetalol, nicardipine, or nitroprusside). Lower gradually — reduce MAP by no more than ~25% in the first hour, then toward ~160/100 mmHg over the next 2–6 hours, normalizing only over 24–48 h — to avoid retinal, cerebral, or renal hypoperfusion. Also assess other end-organ damage (creatinine, urinalysis, ECG/troponin, neuro exam). Do not normalize BP acutely.
Diabetic vs. hypertensive retinopathy
| Feature | Diabetic retinopathy | Hypertensive retinopathy |
|---|---|---|
| Mechanism | Hyperglycemia → pericyte loss, capillary leak & ischemia | Elevated BP → arteriolar sclerosis/spasm |
| Earliest / chronic sign | Microaneurysms | Arteriolar narrowing, AV nicking, copper/silver wiring |
| Hemorrhage | Dot-blot (deep retina) | Flame (superficial nerve-fiber layer) |
| Exudate pattern | Scattered hard exudates, circinate rings | Hard exudates → macular star |
| Defining severe finding | Neovascularization (PDR) → vitreous hemorrhage | Papilledema = malignant HTN |
| Management | Anti-VEGF (DME), PRP for PDR, glycemic control | BP control; IV therapy if hypertensive emergency |
- New diabetic — when to screen? Type 2 → dilated exam now (at diagnosis); Type 1 → in 5 years
- Diabetic macular edema (central vision loss, retinal thickening)? → intravitreal anti-VEGF first-line (± focal/grid laser)
- Proliferative disease / neovascularization? → panretinal photocoagulation (PRP) ± anti-VEGF
- Sudden painless vision loss + diabetes + no fundus view? → suspect vitreous hemorrhage; get B-scan ultrasound; vitrectomy if it fails to clear
- Papilledema + severely elevated BP? → hypertensive emergency: titratable IV antihypertensive; lower MAP ≤25% in the first hour (then ~160/100 over 2–6 h), not to normal
- Cotton wool spots but normotensive & non-diabetic? → look for HIV, SLE, anemia, or emboli
The "4-2-1 rule" flags severe non-proliferative diabetic retinopathy — a patient at high risk of progressing to proliferative disease. Diagnose severe NPDR if any one of:
- 4 quadrants of diffuse intraretinal hemorrhages / microaneurysms, OR
- 2 or more quadrants of venous beading, OR
- 1 or more quadrant of IRMA (intraretinal microvascular abnormalities)
Meeting 4-2-1 means neovascularization (PDR) is imminent, so these patients need close follow-up and often earlier treatment (PRP and/or anti-VEGF).
Practice Ophthalmology now
Board-style questions, spaced-repetition flashcards, and a Socratic AI tutor — free to start.